DK1187603T3 - Kombinationsterapi tl at bevirke vægttab og at behandle obesitet - Google Patents

Kombinationsterapi tl at bevirke vægttab og at behandle obesitet

Info

Publication number
DK1187603T3
DK1187603T3 DK00939884T DK00939884T DK1187603T3 DK 1187603 T3 DK1187603 T3 DK 1187603T3 DK 00939884 T DK00939884 T DK 00939884T DK 00939884 T DK00939884 T DK 00939884T DK 1187603 T3 DK1187603 T3 DK 1187603T3
Authority
DK
Denmark
Prior art keywords
weight loss
combination therapy
treat obesity
cause weight
phentermine
Prior art date
Application number
DK00939884T
Other languages
Danish (da)
English (en)
Inventor
Thomas Najarian
Original Assignee
Vivus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus Inc filed Critical Vivus Inc
Application granted granted Critical
Publication of DK1187603T3 publication Critical patent/DK1187603T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK00939884T 1999-06-14 2000-06-14 Kombinationsterapi tl at bevirke vægttab og at behandle obesitet DK1187603T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13902299P 1999-06-14 1999-06-14
US17856300P 2000-01-26 2000-01-26
US18126500P 2000-02-09 2000-02-09
PCT/US2000/016434 WO2000076493A1 (fr) 1999-06-14 2000-06-14 Therapie combinee permettant de perdre du poids et de traiter l'obesite

Publications (1)

Publication Number Publication Date
DK1187603T3 true DK1187603T3 (da) 2007-12-17

Family

ID=27385274

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00939884T DK1187603T3 (da) 1999-06-14 2000-06-14 Kombinationsterapi tl at bevirke vægttab og at behandle obesitet

Country Status (10)

Country Link
EP (5) EP1187603B1 (fr)
AT (1) ATE369126T1 (fr)
AU (1) AU770068B2 (fr)
CA (2) CA2377330C (fr)
CY (1) CY1106974T1 (fr)
DE (1) DE60035870T2 (fr)
DK (1) DK1187603T3 (fr)
ES (4) ES2542868T3 (fr)
PT (1) PT1187603E (fr)
WO (1) WO2000076493A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
BR0112519A (pt) 2000-07-07 2004-03-30 Ortho Mcneil Pharm Inc Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
PT1333887E (pt) 2000-10-30 2006-10-31 Ortho Mcneil Pharm Inc Metodo de tratamento de desordens musculares
EP1345602B1 (fr) * 2000-11-30 2010-07-21 Novodermix International Limited Cicatrisation des lesions
CA2478183C (fr) 2002-03-12 2010-02-16 Merck & Co. Inc. Amides substitues
CA2483464C (fr) 2002-05-17 2011-12-20 Duke University Procede de traitement de l'obesite
KR20050096915A (ko) * 2002-12-13 2005-10-06 시락 아게 안정한 토피라메이트 제제
ES2303085T3 (es) 2003-04-29 2008-08-01 Orexigen Therapeutics, Inc. Composiciones que afectan a la perdida de peso.
JP2007517901A (ja) 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AU2006249577A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
BRPI0618918B8 (pt) 2005-11-22 2021-05-25 Nalpropion Pharmaceuticals Llc uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
EP2026790A2 (fr) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Thérapie combinée pour le traitement de l'épilepsie et de troubles apparentés
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US7780730B2 (en) 2006-09-25 2010-08-24 Iyad Saidi Nasal implant introduced through a non-surgical injection technique
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
KR20190042766A (ko) * 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2014213552B2 (en) * 2007-06-13 2016-11-24 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
US8071557B2 (en) 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2010059586A1 (fr) 2008-11-19 2010-05-27 Entrigue Surgical, Inc. Appareils et procédés de correction de l'effondrement de la valve nasale
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
WO2013028909A1 (fr) * 2011-08-25 2013-02-28 Sova Pharmaceuticals, Inc. Thérapie combinée pour le traitement de troubles respiratoires liés au sommeil
EP2858640B1 (fr) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition à être utilisée dans une méthode de traitement de la surcharge pondérale et de l'obésité dans de patients présentant un risque cardiovasculaire élevé
PT2961350T (pt) 2013-02-27 2018-05-09 Spirox Inc Implantes nasais e sistemas
WO2014134477A1 (fr) * 2013-02-28 2014-09-04 Livelight Llc Méthodes et systèmes de traitement des individus en surpoids
EP3086662B1 (fr) 2013-12-05 2017-09-13 Givaudan S.A. Composés organiques ayant des propriétés de modification du gout
JP6656227B2 (ja) 2014-08-26 2020-03-04 スピロックス, インク.Spirox, Inc. 鼻インプラントと使用システム及び使用方法
AU2016326676B2 (en) 2015-09-25 2021-07-08 Spirox, Inc. Nasal implants and systems and method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
FR2684101B1 (fr) * 1991-11-22 1993-12-31 Adir Cie Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5498629A (en) 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US5795895A (en) 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування

Also Published As

Publication number Publication date
AU5489600A (en) 2001-01-02
EP1187603A4 (fr) 2004-02-11
EP1187603A1 (fr) 2002-03-20
EP2305226B1 (fr) 2015-05-06
CA2377330C (fr) 2009-11-24
ATE369126T1 (de) 2007-08-15
EP2305227A1 (fr) 2011-04-06
EP2305227B1 (fr) 2015-05-06
EP1187603B1 (fr) 2007-08-08
EP2305226A1 (fr) 2011-04-06
ES2542868T3 (es) 2015-08-12
DE60035870D1 (de) 2007-09-20
ES2542892T3 (es) 2015-08-12
EP2305228B1 (fr) 2015-05-06
EP2308481B1 (fr) 2015-05-06
EP2308481A1 (fr) 2011-04-13
CY1106974T1 (el) 2012-09-26
WO2000076493A1 (fr) 2000-12-21
CA2686633A1 (fr) 2000-12-21
ES2542891T3 (es) 2015-08-12
DE60035870T2 (de) 2008-05-08
CA2377330A1 (fr) 2000-12-21
EP2305228A1 (fr) 2011-04-06
PT1187603E (pt) 2007-11-16
ES2291215T3 (es) 2008-03-01
AU770068B2 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
DK1187603T3 (da) Kombinationsterapi tl at bevirke vægttab og at behandle obesitet
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
DK1333887T3 (da) Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DK0754176T3 (da) Hidtil ukendte carbamater og urinstoffer som modifikatorer for multidrugsresistens
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
CY1113610T1 (el) Συνθεσεις και μεθοδοι για αγωγη μιτοχονδριακων παθησεων
TR199801315T2 (xx) X sendromunun tedavisi i�in bir ppar-alpha ve ppar-gamma antagonistinin kullan�lmas�.
DE59611341D1 (de) Verwendung von saccharid-konjugaten
BR9814923A (pt) Método para tratamento de doença de alzheimer
ATE232396T1 (de) Oxydiertes thymosin beta 4
DK0858504T3 (da) Diagnostiske midler mod og behandlinger af periodontale sygdomme
EP0824917A3 (fr) Utilisation d'un serotonine agoniste du 5-HT1F dans la fabrication d'un médicament pour le traitement ou l'amélioration du rhume ou de la rhinite allergique
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
NO984160L (no) FremgangsmÕte for behandling eller forebyggelse av interstitiell cystitt
DE60023333D1 (de) Schaukel für behinderte
DE60003289D1 (de) Kombinationstherapie für lymphoproliferative krankheiten
NO20053023L (no) Synergistisk kombinasjon omfattende roflumilas og (R,R)-formoterol
ATE139698T1 (de) Mittel zur behandlung chronischer ermüdungserscheinungen
EP1825851A3 (fr) Thérapie combinée permettant de perdre du poids et de traiter l'obésité
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens